TrialJournal of neurology2026

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

James F Howard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.